| 9.4 0.13 (1.4%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 12.7 | 1-year : | 14.84 |
| Resists | First : | 10.88 | Second : | 12.7 |
| Pivot price | 9.48 |
|||
| Supports | First : | 7.7 | Second : | 5.74 |
| MAs | MA(5) : | 9.14 |
MA(20) : | 9.17 |
| MA(100) : | 7.32 |
MA(250) : | 4.83 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 28.8 |
D(3) : | 35.6 |
| RSI | RSI(14): 56.7 |
|||
| 52-week | High : | 10.88 | Low : | 1.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BNTC ] has closed above bottom band by 44.4%. Bollinger Bands are 38% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.72 - 9.76 | 9.76 - 9.81 |
| Low: | 9.14 - 9.19 | 9.19 - 9.24 |
| Close: | 9.32 - 9.4 | 9.4 - 9.47 |
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Wed, 24 Jul 2024
Benitec Biopharma Inc. (NASDAQ:BNTC) to Post FY2024 Earnings of ($5.45) Per Share, Leerink Partnrs Forecasts - MarketBeat
Wed, 24 Jul 2024
Benitec Biopharma Inc. to Post FY2024 Earnings of ($5.45) Per Share, Leerink Partnrs Forecasts (NASDAQ:BNTC) - Defense World
Tue, 23 Jul 2024
Benitec Biopharma (NASDAQ:BNTC) Upgraded by Leerink Partnrs to Strong-Buy - MarketBeat
Mon, 22 Jul 2024
Benitec Biopharma (NASDAQ:BNTC) Now Covered by Analysts at SVB Leerink - Defense World
Mon, 01 Jul 2024
Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 6.01e+006 (%) |
| Held by Institutions | 9.2 (%) |
| Shares Short | 13 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.141e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -307 % |
| Return on Assets (ttm) | 28.5 % |
| Return on Equity (ttm) | -115.7 % |
| Qtrly Rev. Growth | 7000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -290.86 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -9.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 2.04 |
| Dividend | 0 |
| Forward Dividend | 92270 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|